A First-in-Human Study of BNZ132-1-40

Completed · Phase 1

Conditions studied: Healthy

In brief

This is an open-label, single ascending dose study to characterize the safety and PK/PD profile of IV BNZ132-1-40, a novel peptide inhibitor of multiple cytokines in the IL-2 family.

Key facts

Study ID

NCT03046459

Run by

Bioniz Therapeutics

People needed

18

Starts

2016-11-01

Expected to finish

2017-06-05

Last updated by the study team

2017-06-22

Who can join

Age: 18 and older, up to 50. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• males and non-pregnant, non-lactating females
• no ongoing clinically significant medical condition
• willing and able to provide informed consent
• no use of Rx or OTC medications, other than oral contraceptives

You may not qualify if…

• Recent systemic infections
• Clinically-significant abnormal clinical labs, ECG or physical examination
• Immunization 30 days prior to study

Where it is running

• Celerion — Phoenix, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.